287 related articles for article (PubMed ID: 32009195)
1. Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis.
Condreay LD; Parham LR; Qu XA; Steinfeld J; Wechsler ME; Raby BA; Yancey SW; Ghosh S
Rheumatol Int; 2020 Aug; 40(8):1301-1307. PubMed ID: 32009195
[TBL] [Abstract][Full Text] [Related]
2. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ;
N Engl J Med; 2017 May; 376(20):1921-1932. PubMed ID: 28514601
[TBL] [Abstract][Full Text] [Related]
3. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
7. A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
Nara M; Saito M; Abe F; Komatsuda A; Wakui H; Takahashi N
Intern Med; 2019 Dec; 58(24):3583-3587. PubMed ID: 31391393
[TBL] [Abstract][Full Text] [Related]
8. Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis.
Ikeda T; Komatsu T; Yokoyama K; Takahashi K; Kawakami T
J Dermatol; 2021 Apr; 48(4):529-532. PubMed ID: 33305381
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
10. Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis.
Higashitani K; Yoshimi R; Sato Y; Watanabe T; Ihata A
Mod Rheumatol Case Rep; 2022 Jan; 6(1):87-92. PubMed ID: 34473835
[TBL] [Abstract][Full Text] [Related]
11. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
[TBL] [Abstract][Full Text] [Related]
12. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
[TBL] [Abstract][Full Text] [Related]
13. [Anti-IL-5 in severe asthma associated with eosinophilic granulomatosis with polyangiitis. Real-life study].
Akdime F; Habib S; Regard L; Terrier B; Cohen P; Mouthon L; Guillevin L; Burgel PR; Honore I; Puéchal X; Roche N
Rev Mal Respir; 2023; 40(9-10):732-742. PubMed ID: 37923651
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
Doubelt I; Pulenzas N; Carette S; Pagnoux C;
Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
[TBL] [Abstract][Full Text] [Related]
15. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Pagnoux C; Groh M
Expert Rev Clin Immunol; 2016 Oct; 12(10):1059-67. PubMed ID: 27191665
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
Ennis D; Lee JK; Pagnoux C
Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
[TBL] [Abstract][Full Text] [Related]
17. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
18. Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial.
Puéchal X; Pagnoux C; Baron G; Quémeneur T; Néel A; Agard C; Lifermann F; Liozon E; Ruivard M; Godmer P; Limal N; Mékinian A; Papo T; Ruppert AM; Bourgarit A; Bienvenu B; Geffray L; Saraux JL; Diot E; Crestani B; Delbrel X; Sailler L; Cohen P; Le Guern V; Terrier B; Groh M; Le Jeunne C; Mouthon L; Ravaud P; Guillevin L;
Arthritis Rheumatol; 2017 Nov; 69(11):2175-2186. PubMed ID: 28678392
[TBL] [Abstract][Full Text] [Related]
19. Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions.
Ushio Y; Wakiya R; Kato M; Kameda T; Nakashima S; Shimada H; Mansour MMF; Sugihara K; Miyashita T; Kadowaki N; Dobashi H
Mod Rheumatol Case Rep; 2021 Jul; 5(2):327-332. PubMed ID: 33533698
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.
Faverio P; Bonaiti G; Bini F; Vaghi A; Pesci A
Ther Clin Risk Manag; 2018; 14():2385-2396. PubMed ID: 30573961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
